¡¾ÕªÒª¡¿ Ä¿µÄ ÆÀ¼Û¸´·½»Ç°·¼×¿Ú¶ñßò·Ö±ðÓëÌæ¿¨Î÷ÁÖ/¿ËÀάËᡢͷæßßßͪ/Êæ°Í̹Á½Ö֦ª²ÄÚõ£°·Ã¸ÒÖÖÆ¼ÁÁªºÏÓ¦ÓöÔÓÚÁÙ´²·ÖÀë30ÖêÊÈÂóÑ¿¹ÑÑøµ¥°û¾úµÄÌåÍâÁªºÏ¿¹¾úЧӦ¡£·½·¨ ²ÉÓÃÆåÅÌ·¨Éè¼Æ£¬Î¢Á¿ÈâÌÀÏ¡ÊÍ·¨²â¶¨²»Í¬Å¨¶È×éºÏµÄ2×鿹¾úÒ©Îï¶Ô30ÖêÊÈÂóÑ¿¹ÑÑøµ¥°û¾úµÄ×îµÍÒÖ¾úŨ¶È£¬²¢¼ÆËãÁªºÏÒÖ¾úÖ¸Êý(FIC)£¬ÅжÏÁªºÏЧӦ¡£½á¹û ¸´·½»Ç°·¼×¿Ú¶ñßò¶ÔÊÈÂóÑ¿¹ÑÑøµ¥°û¾úµÄMICΪ2/38£¬ÓëÌæ¿¨Î÷ÁÖ/¿ËÀάËᡢͷæßßßͪ/Êæ°Í̹ÁªºÏÓ¦ÓÃºó£¬ÆäMIC50ÏÔÖø½µµÍÖÁ0.5/9.5£¬FICÖ¸Êý·Ö²¼·¶Î§Ö÷ÒªÔÚ0¡«1¡£½áÂÛ ¸´·½»Ç°·¼×¿Ú¶ñßòÓëÌæ¿¨Î÷ÁÖ/¿ËÀάËᡢͷæßßßͪ/Êæ°Í̹Á½Ö֦ª²ÄÚõ£°·/øÒÖÖÆ¼ÁÁªºÏÓ¦Óú󣬶ÔÊÈÂóÑ¿¹ÑÑøµ¥°û¾ú±íÏÖΪÐͬ×÷ÓúÍÏà¼Ó×÷Ó㬲¢ÒÔÐͬ×÷ÓÃΪÖ÷¡£
¡¾¹Ø¼ü´Ê¡¿ ÊÈÂóÑ¿¹ÑÑøµ¥°û¾ú ¸´·½»Ç°·¼×¿Ú¶ñßò Ìæ¿¨Î÷ÁÖ/¿ËÀάËá Í·æßßßͪ/Êæ°Í̹ ÁªºÏÒ©Ãô
In vitro antibacterial activity of compound sulfamethoxazole combined
ABSTRACT Objective To evaluate the antibiotic effects of SMZ/TMP combined with TIPC/CA, CPZ/SB respectively against 30 Stenotrophomonas maltophilia. Methods The protocol was designed by checkerboard method and the MIC of two groups antibiotics against 30 Stenotrophomonas maltophilia was determined by dilution method and the FIC index was calculated according to MIC results. Results The in vitro antibacterial activity of MICs of combinations were lower than those of 3 drugs tested alone. The range of the FIC index was mainly between 0¡«1. Conclusion The FIC index indicated that synergism and additiª²vity of SMZ/TMP combined with TIPC/CA, CPZ/SB respectively against 30 Stenotrophomonas maltophilia.
KEY WORDS Stenotrophomonas maltophilia; Compound sulfamothoxazole; Ticarcillin/clavulanic acid; Cefoperazone/sulbactam; FIC
ÊÈÂóÑ¿¹ÑÑøµ¥°û¾ú(Stenotrophomonas maltoª²philia)ÊÇÐèÑõ¡¢·Ç·¢½ÍµÄ¸ïÀ¼ÒõÐԸ˾ú£¬¸Ã¾ú¹ã·º·Ö²¼ÓÚ×ÔÈ»½ç£¬ÎªÖ÷ÒªµÄÌõ¼þÖ²¡¾úºÍÔºÄÚ¸ÐȾµÄ²¡Ô¾úÖ®Ò»£¬¶à·¢ÉúÓÚÀÏÄêÈËÇÒ³¤ÆÚʹÓùãÆ×¿¹ÉúËØºÍ½øÐÐÇÖÈëÐÔÖÎÁÆ»¼ÕߵĺôÎüµÀ±ê±¾ÖС£´Ë¾ú¶Ô³£ÓõĿ¹ÉúËØÓнϸߵÄÄÍÒ©ÐÔ£¬ÇÒ¶ÔÑǰ·ÅàÄÏÌìÈ»ÄÍÒ©£¬ÁÙ´²ÖÎÁƷdz£À§ÄÑ£¬²¡ËÀÂʽϸߡ£¸´·½»Ç°·¼×¿Ú¶ñßò¡¢Ì濨Î÷ÁÖ/¿ËÀάËᡢͷæßßßͪ/Êæ°Í̹Ãô¸ÐÐÔËäÈ»Ïà¶ÔºÃЩ£¬µ«ÆäÄÍÒ©ÐÔÈÔÔÚ20%ÒÔÉÏ£Û1£Ý£¬ÕâÈýÖÖÒ©ÎïÁÙ´²Éϵ¥¶ÀʹÓÃʱÁÆÐ§²»ÀíÏ룬¶ø²ÉÓÃÁªºÏÓÃÒ©¿ÉÌá¸ßÁÆÐ§¡£±¾ÎÄÄâ̽ÌÖ¸´·½»Ç°·¼×¿Ú¶ñßò·Ö±ðÓëÌæ¿¨Î÷ÁÖ/¿ËÀάËᡢͷæßßßͪ/Êæ°Í̹ÁªºÏÓ¦ÓõÄÌåÍ⿹¾ú»îÐÔ£¬ÎªÁÙ´²ÁªºÏÓÃÒ©£¬¼õÉÙÄÍÒ©¾úÖêÌṩʵÑéÒÀ¾Ý¡£
1 ²ÄÁϺͷ½·¨
¡¡¡¡1.1 ¾úÖê
30ÖêÊÈÂóÑ¿¹ÑÑøµ¥°û¾úÀ´Ô´ÓÚÁÙ´²±ê±¾£¬ÆäÖÐ̵28Ö꣬µ¨ÖÒýÁ÷Îï2Ö꣬¾VITEKÖØÐ¼ø¶¨È·ÈÏ¡£ÖʿؾúΪÍÂ̼ٵ¥°û¾úATCC27853¡£
1.2 ÅàÑø»ù
Ë®½âÀÒµ°°×(MH)ÒºÌåÅàÑø»ù(ÖйúÒ©Æ·ÉúÎïÖÆÆ·¼ì¶¨Ëù)¡£
1.3 ¿¹¾úÒ©Îï
¸´·½»Ç°·¼×¿Ú¶ñßò£Û¼×ÑõÜÐडûǰ·¼×»ùÒì¿Ú¶ñßò(1¡Ã19)£Ý(Ìì½ò½ðÕ¿Ƽ¼·¢Õ¹ÓÐÏÞ¹«Ë¾ÅäÖÆ)£¬Ì濨Î÷ÁÖ/¿ËÀάËᣬÖÐÃÀÊ·¿Ë¹«Ë¾(ÅúºÅ166746£¬´¿¶È94%£¬º¬Ì濨Î÷ÁÖ3g£¬¿ËÀάËá0.2g)£¬Í·æßßßͪ/Êæ°Í̹£¬PfizerÖÆÒ©ÓÐÏÞ¹«Ë¾(ÅúºÅ55839229£¬´¿¶È93%£¬Í·æßßßͪ/Êæ°Í̹Ϊ2¡Ã1)¡£
1.4 ÒÇÆ÷
±È×ÇÒÇ(·¨¹úBioª²Merieux¹«Ë¾²úÆ·)£»Á¬ÐøÎ¢Á¿¼ÓÑùÆ÷ºÍ°ËµÀ΢Á¿¼ÓÑùÆ÷¾ùΪÃÀ¹úEppendorf¹«Ë¾²úÆ·)£»96¿×ƽ°å(Ìì½ò½ðÕ¿Ƽ¼·¢Õ¹ÓÐÏÞ¹«Ë¾)¡£
2 ·½·¨ºÍ½á¹û
2.1 ¾úÐüÒºÅäÖÆ
´ÓÒÑ·Ö´¿²¢¹ýÒ¹ÐÂÏÊÅàÑøµÄϸ¾úƽ°åÉÏÌôÈ¡4¡«5¸ö¾úÂ䣬½ÓÖÖÓÚMHÈâÌÀÖÐÔö¾ú6h£¬¾úÒºÓÃ3mlÈâÌÀÒÔ±È×ÇÒÇУÕý×ǶÈÖÁ1.5¡Á108CFU/ml£¬ÔÙÒÔMHÈâÌÀÏ¡ÊÍÖÁ1.5¡Á105CFU/ml¡£
2.2 ¿¹¾úÒ©Îï´¢±¸ÒºÅäÖÆ
Ìæ¿¨Î÷ÁÖ/¿ËÀάËᡢͷæßßßͪ/Êæ°Í̹ÓÃpH6.0µÄPBS»º³åÒºÅä³É×îÖÕŨ¶ÈΪ1920¦Ìg/mlµÄ¿¹ÉúËØ´¢±¸Òº¡£